We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Repros Therapeutics Inc. (NASDAQ: RPRX) to Allergan plc for $0.67 per share.
The investigation concerns whether the Board of Repros Therapeutics breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Allergan plc is underpaying for Repros Therapeutics shares, thus unlawfully harming Repros Therapeutics shareholders.
To receive more information, please fill out the form.